|
|||||
|
|
Phase 2 study of LY3023414 in patients with advanced endometrial cancer harboring activating mutations in the PI3K pathway |
|
| Authors: | Maria M. Rubinstein MD David M. Hyman MD Imogen Caird BA Helen Won MS Krysten Soldan BSN Kenneth Seier MS Alexia Iasonos PhD William P. Tew MD Roisin E. O’Cearbhaill MD Rachel N. Grisham MD Martee L. Hensley MD Tiffany Troso-Sandoval MD Paul Sabbatini MD Joyce Guillen BS S. Duygu Selcuklu PhD Catherine Zimel BS Jean Torrisi MD Carol Aghajanian MD Vicky Makker MD |
| Affiliation: | 1. Gynecologic Medical Oncology Service, Memorial Sloan Kettering Cancer Center, New York, New York;2. Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York;3. Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York;4. Gynecologic Medical Oncology Service, Memorial Sloan Kettering Cancer Center, New York, New York Weill Cornell Medical College, New York, New York;5. Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York |
| Abstract: | |
| Keywords: | advanced dual PI3K/mTOR inhibitor endometrial cancer LY3023414 PI3K pathway |